AstraZeneca (AZN) announced that a Phase 3 clinical trial evaluating its TAGRISSO (osimertinib) as second-line treatment in patients with EGFR T790M mutation-positive, locally advanced and metastatic non-small cell lung cancer (NSCLC) met its primary endpoint of a statistically valid increase in progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The treatment group also showed clinically meaningful increases in objective response rate, disease control rate and duration of response. Complete data will be presented at an upcoming medical conference.